<DOC>
	<DOCNO>NCT00823992</DOCNO>
	<brief_summary>This 2 arm study ass efficacy , safety tolerability taspoglutide compare placebo obese patient type 2 diabetes mellitus inadequately control metformin monotherapy . Patients randomize receive taspoglutide ( 10mg sc weekly 4 week follow 20mg weekly ) placebo sc , addition prescribe , pre-existing metformin therapy.After first 24 week , patient placebo switch taspoglutide 20mg weekly ( 4 week taspoglutide 10mg weekly ) The anticipated time study treatment 12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Taspoglutide Versus Placebo Treatment Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>adult patient , 1875 year age ; type 2 diabetes mellitus , receive metformin stable dose &gt; =1500mg/day least 12 week ; HbA1c &gt; =6.5 % &lt; =9.5 % screening ; BMI &gt; =30 &lt; =50 kg/m2 screen ; stable weight +/5 % least 12 week prior screen . history type 1 diabetes acute metabolic diabetic complication ketoacidosis hyperosmolar coma within past 6 month ; evidence clinically significant diabetic complication ; myocardial infarction , coronary artery bypass surgery , posttransplantation cardiomyopathy stroke within past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>